comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 23:33:02 - browse：1799

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： CRISPR gene editing developments we’re watching in 2024

WSS

Biohaven protein

Latest bird flu infection made farmworker sicker than earlier cases

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Heat waves linked to early deliveries, preterm births in new study

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

knowledge

comprehensive

explore

Wildfire smoke exposes gaps in outdoor worker protections

Adam's Biotech Scorecard: Do Sarepta's exon

Duchenne breakthrough therapy leaves behind pioneering families

How to keep neuroscience’s past racism from being its future

Guidelines to prevent youth baseball injuries need more muscle

SEC charges former device maker CEO with $41 million fraud

Medical leaders decry Supreme Court decision on affirmative action

Health insurers say they are turning to AI to cut costs, improve care

Trump demands the U.S. pay no more for drugs than other countries … again

Three trends to watch in biotech in 2024

explore

Childbirth

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Akili, maker of video game for ADHD, to be acquired for 34 million

Prime Medicine, Myeloid Therapeutics clash over genome

Do more moles mean more problems? Not so, says new study

Medicare Advantage beneficiaries sue Humana over algorithm use

explore

focus

entertainment

explore